FDA 483 - Lovelace Biomedical Research Institute - January 27, 2026

An FDA inspection of Lovelace Biomedical Research Institute in Albuquerque, NM, a GLP Laboratory Facility, revealed two significant issues. The facility failed to retain all raw data generated from nonclinical laboratory studies and did not assure that challenge agents were appropriately tested for identity. These observations indicate deficiencies in data integrity and quality control practices.